Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily ...

Activist investor Starboard Value claims the pharma giant’s former CEO and CFO were “threatened” into backing current ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...